Oğuzhan PARLAKKILIÇ, Egemen AVCI, Fatih KURTULUŞ, Orhun SİNANOĞLU

Gastrik Primeri Olan Mesane Yüzük Hücreli Adenokarsinom: Olgu Sunumu

Primer mesane tümörleri sık görülen ürolojik kanserlerdir. Uzak bir organ kaynaklı metastatik mesane tümörleri ise oldukça nadirdir. Metastatik mesane tümörleri tüm mesane tümörlerinin % 2sinden az görülür ve genellikle melanom, meme kanseri, gastrik kanser kaynaklıdır. Yüzük hücreli mesane kanseri oldukça nadir görülür ve tüm mesane kanserlerinin yaklaşık % 2,4ünü oluşturur. Biz bu yazımızda 2 yıl önce primer mide kanseri nedeniyle total gastrektomi ve sol pnömonektomi operasyonları geçiren 68 yaşındaki bir hastayı sunduk. Hastamızda, rutin kontroller sırasında, ultrasonografi ve Bilgisayarlı Tomografi BT tetkiklerinde bilateral grade 1-2 hidronefroz ile birlikte mesane duvar kalınlaşması tespit edildi. Mesane tümörü tespit edilip transüretral rezeksiyon yapıldı. Histopatolojik değerlendirme sonucu yüzük hücreli mesane adenokarsinomu geldi.

Anahtar Kelimeler:

Yüzük hücreli adenokarsinom, mesane tümörü, mide karsinomu

Signet-Ring Cell Adenocarcinoma Of Urinary Bladder Having Primary Gastric Origine: Case Report

Primary bladder tumor is a frequent urological malignancy, whereas the incidence of metastatic bladder tumor from a distant organ is quite rare. Metastatic bladder tumors are responsible for less than 2 % of all bladder tumors and originate most commonly from a melanoma, breast cancer, and gastric cancer. Signet ring cell cancer is a rare type of bladder malignancy, accounting for approximately 0,24% of all urinary bladder malignancy. We report a case of a 68 years-old woman who underwent total gastrectomy and left pneumonectomy 2 years ago. On routine control, thickening of bladder wall with bilateral grade 1-2 hydronephrosis was detected on ultrasonography and computerized tomography scan. A bladder tumor was detected and resected with transuretral resection. The histopathological examination revealed secondary Signet ring cell adenocarcinoma of the urinary bladder.

Keywords:

Signet ring cell adenocarcinoma, bladder tumor, stomach carcinoma,

PDF

___

1. Kerem Okutur, Orhan Ender Eren, Gokhan Demir. Metastasis of Gastric Signet-Ring Cell Carcinoma to the Urinary Bladder: A case report and Review of the literature. Case reports in Oncological Medicine, 2015 Article ID 127516 http://dx.doi. org/10.1155/2015/127516
2. J. Michels, S.Barbour, D. Cavers and K.N. Chi.’ Metastatic signet ring cell cancer of the bladder responding to chemotherapy with capacitabine: case report and review of the literature. Can Urol Assoc J. 2010; 4(2): 55–57
3. W.Song, S.J, Wu, Y.L.He et al. ‘ Clinicopathological features and survival of patients with colorectal mucinous, signet-ring cell or non mucinous adenocarcinoma Chinese Medical Journal, 2009;1(3): 122-125
4. J Singh, V. Zherebitskiy, D.Grynspan, PM Czaykowski Metastatic signet ring cell adenocarcinoma of the bladder: responsive to treatment Journal of Canadian Urological Association 2012; 6: 15-19
5. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: A systemic review and meta-analysis based on aggregate data J Clin Oncol. 2006; 24:2093-2099
6. Van Cutsem E, Mosieyenko VM, Tjulandin S, et al V325 Study Group. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;1;24(31):4991-4997.
7. Bang YJ, Van Cutsem E, Feyereislova A, et al. ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastrooesophageal junction cancer (ToGA): a phase 3, openlabel, randomised controlled trial. Lancet. 2010 Aug 28;376(9742):687-697.